Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

BACKGROUND: Osteosarcoma (OS) is the most common primary bone tumour in children and young adults. Despite improved prognosis, metastatic or relapsed OS remains largely incurable and no significant improvement has been observed in the last 20 years. Therefore, the search for alternative agents in OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Pignochino, Ymera, Grignani, Giovanni, Cavalloni, Giuliana, Motta, Manuela, Tapparo, Marta, Bruno, Stefania, Bottos, Alessia, Gammaitoni, Loretta, Migliardi, Giorgia, Camussi, Giovanni, Alberghini, Marco, Torchio, Bruno, Ferrari, Stefano, Bussolino, Federico, Fagioli, Franca, Picci, Piero, Aglietta, Massimo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804605/
https://www.ncbi.nlm.nih.gov/pubmed/20003259
http://dx.doi.org/10.1186/1476-4598-8-118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804605/
https://www.ncbi.nlm.nih.gov/pubmed/20003259
http://dx.doi.org/10.1186/1476-4598-8-118

Ejemplares similares